Evidence map›Paper›PMID 38699509›Full record

ArticleAdvanced therapeutics2019

Advances in Receptor-Mediated, Tumor-Targeted Drug Delivery.

Danielle E Large, Jonathan R Soucy, Jacob Hebert, Debra T Auguste

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Exploring multiple drug actions of a CaNaunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. EJNMMI radiopharmacy and chemistry · 2025
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Danielle E LargeDepartment of Chemical Engineering, Northeastern University, 360 Huntington Ave., Boston, MA 02115, USA.
Jonathan R SoucyDepartment of Chemical Engineering, Northeastern University, 360 Huntington Ave., Boston, MA 02115, USA.
Jacob HebertDepartment of Chemical Engineering, Northeastern University, 360 Huntington Ave., Boston, MA 02115, USA.
Debra T AugusteDepartment of Chemical Engineering, Northeastern University, 360 Huntington Ave., Boston, MA 02115, USA.

Funding

Personalized Therapeutics for Inhibiting Breast Cancer MetastasisDP2CA174495 · NCI · NORTHEASTERN UNIVERSITY · PI AUGUSTE, DEBRA · 2012 to 2017
$2.8M
NCI NIH HHS DP2 CA174495
6 · The paper itself

Abstract

Receptor-mediated drug delivery presents an opportunity to enhance therapeutic efficiency by accumulating drug within the tissue of interest and reducing undesired, off-target effects. In cancer, receptor overexpression is a platform for binding and inhibiting pathways that shape biodistribution, toxicity, cell binding and uptake, and therapeutic function. This review will identify tumor-targeted drug delivery vehicles and receptors that show promise for clinical translation based on quantitative in vitro and in vivo data. The authors describe the rationale to engineer a targeted drug delivery vehicle based on the ligand, chemical conjugation method, and type of drug delivery vehicle. Recent advances in multivalent targeting and ligand organization on tumor accumulation are discussed. Revolutionizing receptor-mediated drug delivery may be leveraged in the therapeutic delivery of chemotherapy, gene editing tools, and epigenetic drugs.

Indexed as

cancerreceptor targetingtargeted drug deliverytherapeutictumor accumulation

Identifiers

PMID38699509
PMCPMC11064891

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.